Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study Assessing Single and Multiple Doses of Hepatitis C Virus (HCV) Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects.

Next Previous
X
Search
Trial Profile

A Phase I/IIa Study Assessing Single and Multiple Doses of Hepatitis C Virus (HCV) Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IDX 320 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 26 Oct 2011 Results will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2011)
    • 01 Nov 2010 Results were presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases.
    • 07 Sep 2010 Status changed from recruiting to completed. According to an Idenix media release, all planned studies of IDX 320 to date have been completed and there are currently no healthy volunteers or patients receiving this drug.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top